Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

77265

	registered interest
	date	10/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lyme Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether, in December 2011, the Clinical Pathology Accreditation Service was made aware of modifications by the Health Protection Agency’s Lyme Borreliosis Unit to the Trinity Biotech immunoblot kit to be used for testing human cerebrospinal fluid.
	tabling member printed	The Countess of Mar
	uin	HL999
	answer	answer is ministerial correction date of answer 24/07/2014 answer text <p>The former Health Protection Agency's Lyme Borreliosis Unit (HPA LBU) was accredited by Clinical Pathology Accreditation who had access to, and was able to review, all the standard operating procedures of the unit.</p><p> </p><p>The Trinity Biotech Lyme Western Blot is a qualitative in vitro assay for the detection of Immunoglobulin (IgG or IgM) antibodies in human samples against specific antigens/proteins of <em>Borrelia afzelii, Borrelia garinii and Borrelia burgdorferi</em>. The Trinity Biotech Lyme Western Blot is intended as a confirmatory assay for use in testing human samples which have been previously found to be positive or equivocal using an Enzyme Immunoassay and Immunofluroescent Assay or other appropriate screening method. Positive second-tier results are supportive evidence of infection with <em>B. burgdorferi</em>. The diagnosis of Lyme disease should be made based on history and symptoms (such as erythema migrans), and other laboratory data, in addition to the presence of antibodies to <em>B. burgdorferi</em>. The Trinity Biotech blot has been in use since 2007 by the former HPA’s LBU for testing cerebrospinal fluid (CSF) and proved very reliable. This technique has also been in use widely across Europe during this period as a diagnostic test using CSF as a sample to support the diagnosis of neuroborreliosis.</p> answering member printed Earl Howe question first answered 24/07/2014 12:32:59 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

77264

	registered interest
	date	10/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lyme Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when the testing of the cerebrospinal fluid of patients suspected of having Lyme disease using the Trinity Biotech kit at the Health Protection Agency’s Lyme Borreliosis Unit began; how many patients' samples were tested in that way; and how many patients were recorded as being positive over that period of time.
	tabling member printed	The Countess of Mar
	uin	HL998
	answer	answer is ministerial correction date of answer 24/07/2014 answer text <p>The Trinity Biotech blot has been in use since 2007 by the former Health Protection Agency's Lyme Borreliosis Unit for testing cerebrospinal fluid (CSF) and proved very reliable. It has also been used in this way by other laboratories in Europe. However, CSF antibodies will not be present if there is no evidence of any other antibodies in the serum. Data is not collected centrally on specific samples from patients as the final diagnosis is made by the clinician on the basis of the test results and the clinical presentation.</p> answering member printed Earl Howe question first answered 24/07/2014 12:31:17 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

58574

	registered interest
	date	05/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mental Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether personality disorder services remain a priority commitment for the National Health Service; and if so, what guidance is provided to NHS England to ensure that quality services continue to be commissioned.
	tabling member printed	Lord Alderdice
	uin	HL99
	answer	answer is ministerial correction date of answer 19/06/2014 answer text Personality disorder services remain a priority commitment for the National Health Service. In 2011 the Government published No health, without mental health, a cross Government mental health outcomes strategy for people of all ages which remains the Government's vision for improving services for people with mental health problems; this specifically includes people with personality disorders. The Mandate to NHS England makes clear that by March 2015, we expect NHS England to make measurable progress towards achieving true parity of esteem between mental and physical health and that everyone who needs it should have timely access to evidence-based services. answering member printed Earl Howe question first answered 19/06/2014 11:56:04 answering member 2000 label Biography information for Earl Howe
	tabling member	3478 label Biography information for Lord Alderdice

76631

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Transplant Surgery
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what they are doing to promote organ transplants.
	tabling member printed	Lord Bourne of Aberystwyth
	uin	HL973
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The six years between April 2008 and April 2014 have seen a strengthening of the donation programme; increasing donation rates by 63% and transplant rates by 47%. The number of people registering for organ donation has increased by over 3 million since 2010 to over 20 million.</p><p> </p><p>A new seven year United Kingdom-wide organ donation and transplantation strategy <em>Taking Organ Transplantation to 2020: A UK strategy</em>, was published by NHS Blood and Transplant (NHSBT) in July 2013. The strategy sets out proposed action to increase consent rates, optimise donation and increase transplants.</p><p> </p><p>NHSBT continues to raise the profile of organ donation through a number of other ways. For example, people can join the Organ Donor Register online, through Facebook, by phone, post, registering with a general practitioner, a Boots pharmacy loyalty card or when applying for a passport. More people from Black, Asian and Minority Ethnic communities are needed to register on the Organ Donor Register and the recently launched Peer Educator Project, sponsored by the Department, training peer educators from the Pakistani Muslim community in Birmingham, is an example of action in this area. The Parliamentary Under-Secretary of State for Public Health (Jane Ellison) wrote to all Members during the National Transplant Week to raise the profile and benefits of organ donation and transplantation. The British Kidney Patient Association and NHS Blood and Transplant also held a reception in Parliament.</p><p> </p> answering member printed Earl Howe question first answered 23/07/2014 14:20:53 answering member 2000 label Biography information for Earl Howe
	tabling member	4282 label Biography information for Lord Bourne of Aberystwyth

76626

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Meningitis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the timetable for the procurement and introduction of the meningitis B vaccine.
	tabling member printed	Baroness Corston
	uin	HL968
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>We are committed to introducing this vaccine as soon as practicable, in line with the Joint Committee on Vaccination and Immunisation’s recommendation, subject to the manufacturer offering the vaccine at a cost-effective price.</p> answering member printed Earl Howe question first answered 23/07/2014 12:36:57 answering member 2000 label Biography information for Earl Howe
	tabling member	215 label Biography information for Baroness Corston

76620

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what is the scale of neurofibromatosis Type 1 in the United Kingdom.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL962
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL960 HL961 question first answered 14/07/2014 16:18:38 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76619

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how they will ensure a co-ordinated response at local level for neurofibromatosis Type 1 sufferers.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL961
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL960 HL962 question first answered 14/07/2014 16:18:38 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76618

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to develop a national service framework for neurofibromatosis Type 1 sufferers.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL960
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL961 HL962 question first answered 14/07/2014 16:18:37 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76617

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Disability Aids
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the impact of the potential internal production of the report required under section 22 of the Chronically Sick and Disabled Persons Act 1970 on the identification of innovation opportunities, particularly for the manufacturing industry and small and medium-sized enterprises.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL959
	answer	answer is ministerial correction date of answer 17/07/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p><em>The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.</em></p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology, and this contract expired in June 2014. The annual cost was £72,268 (figure for final year). The contract was funded by the Department's Policy Research Programme.</p><p> </p><p>The Department has to deliver change in a climate of continuing fiscal challenge and constraint on public spending, and the approach to reporting on assistive technology research and development is aligned with this. The Department does not therefore plan to invite tenders for production of Section 22 reports from 2014-15 and will produce future reports on a smaller scale and of sufficient quality to meet the statutory requirement. This will be done in-house at no additional cost.</p><p> </p><p>As the Government will continue to meet the statutory requirement, no formal consultation on Section 22 has been undertaken or planned.</p><p> </p><p>Reports produced under Section 22, together with other sources of information about Government-funded assistive technology research (including published outputs, project databases, trial registers, websites and other information published by research funders and organisations carrying out research) will continue to make information available that can be used to support the identification of innovation opportunities and the identification and adoption of technology.</p><p> </p> answering member printed Earl Howe grouped question UIN HL897 HL898 HL899 HL900 HL901 HL902 HL957 HL958 question first answered 17/07/2014 11:49:08 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76616

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Disability Aids
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what measures they intend to take in order to ensure that the potential internal production of the report required under section 22 of the Chronically Sick and Disabled Persons Act 1970 will not lead to a reduction in the quality of the report.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL958
	answer	answer is ministerial correction date of answer 17/07/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p><em>The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.</em></p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology, and this contract expired in June 2014. The annual cost was £72,268 (figure for final year). The contract was funded by the Department's Policy Research Programme.</p><p> </p><p>The Department has to deliver change in a climate of continuing fiscal challenge and constraint on public spending, and the approach to reporting on assistive technology research and development is aligned with this. The Department does not therefore plan to invite tenders for production of Section 22 reports from 2014-15 and will produce future reports on a smaller scale and of sufficient quality to meet the statutory requirement. This will be done in-house at no additional cost.</p><p> </p><p>As the Government will continue to meet the statutory requirement, no formal consultation on Section 22 has been undertaken or planned.</p><p> </p><p>Reports produced under Section 22, together with other sources of information about Government-funded assistive technology research (including published outputs, project databases, trial registers, websites and other information published by research funders and organisations carrying out research) will continue to make information available that can be used to support the identification of innovation opportunities and the identification and adoption of technology.</p><p> </p> answering member printed Earl Howe grouped question UIN HL897 HL898 HL899 HL900 HL901 HL902 HL957 HL959 question first answered 17/07/2014 11:49:08 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath